Status:
COMPLETED
Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Classical Hodgkin Lymphoma
Nodular Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
.This study is trying to address change of chemotherapy dosage according to individual patient response to initial cycles of chemotherapy in order to reduce cumulative dose of chemotherapy.The study i...
Detailed Description
Patients were eligible if they had early unfavorable disease or patients who presented with stage III or IV disease .Pt assigned to receive 6 cycles of Bleomycin Etoposide, Doxorubicin, Cyclophosphami...
Eligibility Criteria
Inclusion
- stage I-IIA/B with adverse prognostic or III-IV disease
- Age 18 and Over
- Performance status ECOG 0-3
- Hematopoietic WBC at least 4000/mm3(unless documented bone marrow involvement)
- Hepatic bilirubin no greater then 5 mg/dL
- RENAL:Creatinine no greater than 2.0mg/dL
- not pregnant or nursing
- Fertile patients must use effective contraception
- HIV negative
- No other malignancy within the past 5 years
Exclusion
- \-
Key Trial Info
Start Date :
July 1 1999
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00305149
Start Date
July 1 1999
End Date
December 1 2005
Last Update
March 21 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eldad Dann
Haifa, Israel, 31096